Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer

27 Apr 2017

Abstract excerpt

BACKGROUND: Mutations in the KRAS gene can be detected in about 70-90% of pancreatic cancer (PC) cases. Whether these mutations have a prognostic or predictive value remains elusive. Furthermore, the clinical relevance of the extended RAS (KRAS+NRAS) mutational status is unclear in PC. METHODS: We prospectively defined a PC patient population who received erlotinib-free chemotherapy regimens. A statistically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Treatments and Studies
Share to Pancreatic and Hepatic Oncology Research
Share to Pancreatitis Pathology and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28449008
DOI: 10.1038/bjc.2017.115

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Extended RAS analysis and correlation with overall survival in advanced pancreatic cancerPMID 28449008Read ↗

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer.Semantic proximity Read ↗

Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis.Semantic proximity Read ↗

Oncogenesis and the clinical significance of K-ras in pancreatic adenocarcinoma.Semantic proximity Read ↗

Somatic Mutations in Exocrine Pancreatic Tumors: Association with Patient SurvivalSemantic proximity Read ↗

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.Semantic proximity Read ↗

Impact of KRAS Mutations and Co-mutations on Clinical Outcome in Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.Semantic proximity Read ↗

Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy.Semantic proximity Read ↗

Elevated KRAS protein level is associated with better survival in pancreatic cancerSemantic proximity Read ↗

Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.Semantic proximity Read ↗

EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer.Semantic proximity Read ↗

Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.